Crossmark

Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond

Crossref DOI link: https://doi.org/10.1007/s40259-018-0280-7

Published Online: 2018-05-07

Published Print: 2018-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karo-Atar, Danielle

Bitton, Almog

Benhar, Itai

Munitz, Ariel https://orcid.org/0000-0003-1626-3019
Funding

Funding for this research was provided by:

Israel Cancer Research Fund

Israel Science Foundation (886/15, 2611/16, 1130/17)

United States - Israel Binational Science Foundation (2011244)

Cancer Biology Research Center, Tel Aviv University
License Information

Text and Data Mining valid from 2018-05-07
More Information

Article History

First Online: 7 May 2018

Compliance with Ethical Standards

:

: A.M. is supported by the US–Israel Bi-national Science Foundation (Grant no. 2011244) and the Israel Science Foundation (Grant no. 886/15), the Israel Cancer Research Foundation, the Cancer Biology Research Center, Tel Aviv University. I.B. is supported by the Israel Science Foundation (Grant nos. 2611/16 and 1130/17) and the Reut fund Hematooncology grant from the Cancer Biology Research Center, Tel Aviv University.

: AM is a scientific consultant for GlaxoSmithKline, Compugen and Augmanity Nano LTD. D.K.A. is an employee of Augmanity Nano LTD. I.B. and A.B. declare no conflicts of interest.